Fecal microbiota transplantation (FMT) is a novel therapeutic procedure aiming at restoring a normal intestinal microbiota by application of fecal microorganisms from a healthy subject into the gastrointestinal tract of a patient. FMT is the most effective treatment for recurrent Clostridium difficile infections (CDI). These infections also occur in patients with inflammatory bowel diseases (IBDs), where case series demonstrated a successful treatment of CDI by FMT in 83-92% of patients. The effect of FMT on the activity of IBD has mainly been investigated in ulcerative colitis (UC) patients, including 3 randomized controlled trials. So far, 2 randomized controlled trials showed a superiority of FMT compared to placebo in inducing remission in UC, while 1 study found no significant difference to placebo. The variation in response to FMT between these studies as well as in the uncontrolled trials might be explained by many differences in the way of FMT application, patient pretreatment and patient and donor selection. The data for the use of FMT in Crohn's disease and pouchitis are sparse; currently, no conclusion can be drawn regarding the effectiveness of FMT in these indications. It needs to be noted that cases of IBD activation after FMT have been reported. So far, FMT can only be recommended to be used for the treatment of concomitant CDI in IBD in clinical practice. For treating IBD irrespective of CDI, FMT should be only used in clinical trials. Current forms of FMT, especially protocols using repeated application, are very time and personnel consuming. Future trends are the use of defined stable microbiota preparations, in particular oral preparations, which will enable better and larger controlled trails for investigating FMT in IBD.

Journal Section:
IBD - Environmental Factors
Keywords:
Inflammatory bowel disease, Ulcerative colitis, Crohn’s disease, Clostridium difficile, Fecal microbiota transplantation, Stool transplantation, Intestinal microbiome
1.
Kump PK, Krause R, Allerberger F, Högenauer C: Faecal microbiota transplantation - the Austrian approach. Clin Microbiol Infect 2014;20:1106-1111.
2.
Debast SB, Bauer MP, Kuijper EJ; European Society of Clinical Microbiology and Infectious Diseases: European society of clinical microbiology and infectious diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 2014;20(suppl 2):1-26.
3.
Högenauer C: Clostridium difficile Infektion - Prävention, Diagnose, Therapie. UNI-MED Science, 2013.
4.
Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH, McFarland LV, Mellow M, Zuckerbraun BS: Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 2013;108:478-498.
5.
Kelly CR, Kahn S, Kashyap P, Laine L, Rubin D, Atreja A, Moore T, Wu G: Update on fecal microbiota transplantation 2015: indications, methodologies, mechanisms, and outlook. Gastroenterology 2015;149:223-237.
6.
Kassam Z, Lee CH, Yuan Y, Hunt RH: Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol 2013;108:500-508.
7.
van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, Visser CE, Kuijper EJ, Bartelsman JF, Tijssen JG, Speelman P, Dijkgraaf MG, Keller JJ: Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013;368:407-415.
8.
Gough E, Shaikh H, Manges AR: Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 2011;53:994-1002.
9.
Bauchinger S, Hoffmann KM, Hauer AC, Modl M, Pfleger A, Schweintzger S, Zobel G, Till H, Zaupa P, Schalamon J, Beer M, Krause R, Eherer AJ, Kump P, Högenauer C, Eber E: Einsatz der Fäkalen Mikrobiotatransplantation (Stuhltransplantation) bei fulminanter Clostridium-difficile-Pankolitis und CF. Monatsschrift Kinderheilkunde 2013;161:51.
10.
Trubiano JA, Gardiner B, Kwong JC, Ward P, Testro AG, Charles PG: Faecal microbiota transplantation for severe Clostridium difficile infection in the intensive care unit. Eur J Gastroenterol Hepatol 2013;25:255-257.
11.
Gweon TG, Lee KJ, Kang DH, Park SS, Kim KH, Seong HJ, Ban TH, Moon SJ, Kim JS, Kim SW: A case of toxic megacolon caused by Clostridium difficile infection and treated with fecal microbiota transplantation. Gut Liver 2015;9:247-250.
12.
Zainah H, Hassan M, Shiekh-Sroujieh L, Hassan S, Alangaden G, Ramesh M: Intestinal microbiota transplantation, a simple and effective treatment for severe and refractory Clostridium difficile infection. Dig Dis Sci 2015;60:181-185.
13.
Fischer M, Sipe BW, Rogers NA, Cook GK, Robb BW, Vuppalanchi R, Rex DK: Faecal microbiota transplantation plus selected use of vancomycin for severe-complicated Clostridium difficile infection: description of a protocol with high success rate. Aliment Pharmacol Ther 2015;42:470-476.
14.
Agrawal M, Aroniadis OC, Brandt LJ, Kelly C, Freeman S, Surawicz C, Broussard E, Stollman N, Giovanelli A, Smith B, Yen E, Trivedi A, Hubble L, Kao D, Borody T, Finlayson S, Ray A, Smith R: The long-term efficacy and safety of fecal microbiota transplant for recurrent, severe, and complicated Clostridium difficile infection in 146 elderly individuals. J Clin Gastroenterol 2016;50:403-407.
15.
Aroniadis OC, Brandt LJ, Greenberg A, Borody T, Kelly CR, Mellow M, Surawicz C, Cagle L, Neshatian L, Stollman N, Giovanelli A, Ray A, Smith R: Long-term follow-up study of fecal microbiota transplantation for severe and/or complicated Clostridium difficile infection: a multicenter experience. J Clin Gastroenterol 2016;50:398-402.
16.
Waltz P, Zuckerbraun B: Novel therapies for severe Clostridium difficile colitis. Curr Opin Crit Care 2016;22:167-173.
17.
Song Y, Garg S, Girotra M, Maddox C, von Rosenvinge EC, Dutta A, Dutta S, Fricke WF: Microbiota dynamics in patients treated with fecal microbiota transplantation for recurrent Clostridium difficile infection. PLoS One 2013;8:e81330.
18.
Chang JY, Antonopoulos DA, Kalra A, Tonelli A, Khalife WT, Schmidt TM, Young VB: Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis 2008;197:435-438.
19.
Buffie CG, Bucci V, Stein RR, McKenney PT, Ling L, Gobourne A, No D, Liu H, Kinnebrew M, Viale A, Littmann E, van den Brink MR, Jenq RR, Taur Y, Sander C, Cross JR, Toussaint NC, Xavier JB, Pamer EG: Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature 2015;517:205-208.
20.
Weingarden AR, Chen C, Bobr A, Yao D, Lu Y, Nelson VM, Sadowsky MJ, Khoruts A: Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection. Am J Physiol Gastrointest Liver Physiol 2014;306:G310-G319.
21.
Rahier JF, Magro F, Abreu C, Armuzzi A, Ben-Horin S, Chowers Y, Cottone M, de Ridder L, Doherty G, Ehehalt R, Esteve M, Katsanos K, Lees CW, Macmahon E, Moreels T, Reinisch W, Tilg H, Tremblay L, Veereman-Wauters G, Viget N, Yazdanpanah Y, Eliakim R, Colombel JF; European Crohn's and Colitis Organisation (ECCO): Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2014;8:443-468.
22.
Zollner-Schwetz I, Herzog KA, Feierl G, Leitner E, Schneditz G, Sprenger H, Prattes J, Petritsch W, Wenzl H, Kump P, Gorkiewicz G, Zechner E, Högenauer C: The toxin-producing pathobiont Klebsiella oxytoca is not associated with flares of inflammatory bowel diseases. Dig Dis Sci 2015;60:3393-3398.
23.
Masclee GM, Penders J, Jonkers DM, Wolffs PF, Pierik MJ: Is Clostridium difficile associated with relapse of inflammatory bowel disease? Results from a retrospective and prospective cohort study in the Netherlands. Inflamm Bowel Dis 2013;19:2125-2131.
24.
Ben-Horin S, Margalit M, Bossuyt P, Maul J, Shapira Y, Bojic D, Chermesh I, Al-Rifai A, Schoepfer A, Bosani M, Allez M, Lakatos PL, Bossa F, Eser A, Stefanelli T, Carbonnel F, Katsanos K, Checchin D, Miera IS, Chowers Y, Moran GW; European Crohn's and Colitis Organization (ECCO): Combination immunomodulator and antibiotic treatment in patients with inflammatory bowel disease and Clostridium difficile infection. Clin Gastroenterol Hepatol 2009;7:981-987.
25.
Gombotz E, Leitner E, Zollner-Schwetz I, Krause R, Kornschober C, Wenzl H, Kump P, Petritsch W, Högenauer C: Infections with C. difficile in inflammatory bowel disease patients are difficult to treat and frequently recur. J Crohns Colitis 2016;10:S484.
26.
Borody TJ, Wettstein A, Nowak S, Finlayson SSL: Fecal microbiota transplantation (FMT) eradicates Clostridium difficile infection (CDI) in inflammatory bowel disease (IBD). United European Gastroenterol J 2013;1(suppl 1):A57.
27.
Fischer M, Kelly C, Kao D, Kuchipudi A, Jafri SM, Blumenkehl M, Rex D, Mellow M, Kaur N, Sokol H, Cook G, Phelps E, Sipe B: Outcomes of fecal microbiota transplantation for C. difficile infection in patients with inflammatory bowel disease. Am J Gastroenterol 2014;109:S487.
28.
Jain A, Parian AM, Dudley-Brown S, Lazarev M: Fecal microbiota transplantation is safe and effective for treatment of recurrent clostridium difficile infection in inflammatory bowel disease patients. Gastroenterology 2015;148:S869.
29.
Khanna S, Weatherly RM, Kammer PP, Pardi DS: Long-term follow-up after fecal microbiota transplantation for C. difficile infection in inflammatory bowel disease patients. Gastroenterology 2015;148:S726.
30.
Khoruts A, Rank KM, Newman KM, Viskocil K, Vaughn BP, Hamilton MJ, Sadowsky MJ: Inflammatory bowel disease affects the outcome of fecal microbiota transplantation for recurrent Clostridium difficile infection. Clin Gastroenterol Hepatol 2016;pii:S1542-3565(16)00166-X.
31.
Klymiuk I, Högenauer C, Halwachs B, Thallinger GG, Fricke WF, Steininger C: A physicians' wish list for the clinical application of intestinal metagenomics. PLoS Med 2014;11:e1001627.
32.
Sartor RB: Microbial influences in inflammatory bowel diseases. Gastroenterology 2008;134:577-594.
33.
Bennet JD, Brinkman M: Treatment of ulcerative colitis by implantation of normal colonic flora. Lancet 1989;1:164.
34.
Borody TJ, George L, Andrews P, Brandl S, Noonan S, Cole P, Hyland L, Morgan A, Maysey J, Moore-Jones D: Bowel-flora alteration: a potential cure for inflammatory bowel disease and irritable bowel syndrome? Med J Aust 1989;150:604.
35.
Borody TJ, Warren EF, Leis S, Surace R, Ashman O: Treatment of ulcerative colitis using fecal bacteriotherapy. J Clin Gastroenterol 2003;37:42-47.
36.
Paramsothy S, Kamm M, Walsh A, van den Bogaerde J, Samuel D, Leong R, Connor S, Ng W, Paramsothy R, Kaakoush N, Mitchell H, Xuan W, Lin E, Borody T: Multi-donor intense faecal microbiota transplantation is an effective treatment for resistant ulcerative colitis: a randomised placebo-controlled trial. J Crohns Colitis 2016;10:S14.
37.
Moayyedi P, Surette MG, Kim PT, Libertucci J, Wolfe M, Onischi C, Armstrong D, Marshall JK, Kassam Z, Reinisch W, Lee CH: Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology 2015;149:102-109.e6.
38.
Rossen NG, Fuentes S, van der Spek MJ, Tijssen JG, Hartman JH, Duflou A, Lowenberg M, van den Brink GR, Mathus-Vliegen EM, de Vos WM, Zoetendal EG, D'Haens GR, Ponsioen CY: Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology 2015;149:110-118.e4.
39.
Kump PK, Wurm P, Gröchenig HP, Reiter L, Hoffmann KM, Spindelböck W, Reicht G, Wenzl H, Petritsch W, Gorkiewicz G, Högenauer C: Impact of antibiotic treatment before faecal microbiota transplantation (FMT) in chronic active ulcerative colitis. United European Gastroenterol J 2015;3(5 Suppl): A437.
40.
Kellermayer R, Nagy-Szakal D, Harris RA, Luna RA, Pitashny M, Schady D, Mir SA, Lopez ME, Gilger MA, Belmont J, Hollister EB, Versalovic J: Serial fecal microbiota transplantation alters mucosal gene expression in pediatric ulcerative colitis. Am J Gastroenterol 2015;110:604-606.
41.
Kump PK, Grochenig HP, Lackner S, Trajanoski S, Reicht G, Hoffmann KM, Deutschmann A, Wenzl HH, Petritsch W, Krejs GJ, Gorkiewicz G, Högenauer C: Alteration of intestinal dysbiosis by fecal microbiota transplantation does not induce remission in patients with chronic active ulcerative colitis. Inflamm Bowel Dis 2013;19:2155-2165.
42.
Suskind DL, Singh N, Nielson H, Wahbeh G: Fecal microbial transplant via nasogastric tube for active pediatric ulcerative colitis. J Pediatr Gastroenterol Nutr 2015;60:27-29.
43.
Vermeire S, Joossens M, Verbeke K, Wang J, Machiels K, Sabino J, Ferrante M, Van Assche G, Rutgeerts P, Raes J: Donor species richness determines faecal microbiota transplantation success in inflammatory bowel disease. J Crohns Colitis 2016;10:387-394.
44.
Kao D, Hotte N, Gillevet P, Madsen K: Fecal microbiota transplantation inducing remission in Crohn's colitis and the associated changes in fecal microbial profile. J Clin Gastroenterol 2014;48:625-628.
45.
Zhang FM, Wang HG, Wang M, Cui BT, Fan ZN, Ji GZ: Fecal microbiota transplantation for severe enterocolonic fistulizing Crohn's disease. World J Gastroenterol 2013;19:7213-7216.
46.
Kelly CR, Ihunnah C, Fischer M, Khoruts A, Surawicz C, Afzali A, Aroniadis O, Barto A, Borody T, Giovanelli A, Gordon S, Gluck M, Hohmann EL, Kao D, Kao JY, McQuillen DP, Mellow M, Rank KM, Rao K, Ray A, Schwartz MA, Singh N, Stollman N, Suskind DL, Vindigni SM, Youngster I, Brandt L: Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. Am J Gastroenterol 2014;109:1065-1071.
47.
Cui B, Feng Q, Wang H, Wang M, Peng Z, Li P, Huang G, Liu Z, Wu P, Fan Z, Ji G, Wang X, Wu K, Fan D, Zhang F: Fecal microbiota transplantation through mid-gut for refractory Crohn's disease: safety, feasibility, and efficacy trial results. J Gastroenterol Hepatol 2015;30:51-58.
48.
Fang S, Kraft CS, Dhere T, Srinivasan J, Begley B, Weinstein D, Shaffer VO: Successful treatment of chronic pouchitis utilizing fecal microbiota transplantation (FMT): a case report. Int J Colorectal Dis 2016;31:1093-1094.
49.
Landy J, Walker AW, Li JV, Al-Hassi HO, Ronde E, English NR, Mann ER, Bernardo D, McLaughlin SD, Parkhill J, Ciclitira PJ, Clark SK, Knight SC, Hart AL: Variable alterations of the microbiota, without metabolic or immunological change, following faecal microbiota transplantation in patients with chronic pouchitis. Sci Rep 2015;5:12955.
50.
Frank J, Högenauer C, Gröchenig HP, Hoffmann KM, Reicht G, Wenzl H, Petritsch W, Kump PK: Safety of fecal microbiota transplantation in patients with chronic colitis and immunosuppressive treatement. J Crohns Colitis 2015;9:S245-S246.
51.
Angelberger S, Reinisch W, Makristathis A, Lichtenberger C, Dejaco C, Papay P, Novacek G, Trauner M, Loy A, Berry D: Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation. Am J Gastroenterol 2013;108:1620-1630.
52.
Quera R, Espinoza R, Estay C, Rivera D: Bacteremia as an adverse event of fecal microbiota transplantation in a patient with Crohn's disease and recurrent Clostridium difficile infection. J Crohns Colitis 2014;8:252-253.
53.
Kunde S, Pham A, Bonczyk S, Crumb T, Duba M, Conrad H Jr, Cloney D, Kugathasan S: Safety, tolerability, and clinical response after fecal transplantation in children and young adults with ulcerative colitis. J Pediatr Gastroenterol Nutr 2013;56:597-601.
54.
Greenberg A, Aroniadis O, Shelton C, et al.: Long-term follow-up study of fecal microbiota transplantation (FMT) for inflammatory bowel disease (IBD). Am J Gastroenterol 2013;108:S540.
55.
Cui B, Li P, Xu L, Zhao Y, Wang H, Peng Z, Xu H, Xiang J, He Z, Zhang T, Nie Y, Wu K, Fan D, Ji G, Zhang F: Step-up fecal microbiota transplantation strategy: a pilot study for steroid-dependent ulcerative colitis. J Transl Med 2015;13:298.
56.
Damman CJ, Brittnacher MJ, Westerhoff M, Hayden HS, Radey M, Hager KR, Marquis SR, Miller SI, Zisman TL: Low level engraftment and improvement following a single colonoscopic administration of fecal microbiota to patients with ulcerative colitis. PLoS One 2015;10:e0133925.
57.
Vaughn BP, Gevers D, Ting A, Korzenik JR, Robson SC, Moss AC: Fecal microbiota transplantation induces early improvement in symptoms in patients with active Crohn's disease. Gastroenterology 2014;146:S591.
58.
Suskind DL, Brittnacher MJ, Wahbeh G, Shaffer ML, Hayden HS, Qin X, Singh N, Damman CJ, Hager KR, Nielson H, Miller SI: Fecal microbial transplant effect on clinical outcomes and fecal microbiome in active Crohn's disease. Inflamm Bowel Dis 2015;21:556-563.
© 2016 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2016
You do not currently have access to this content.